Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Finch

My life’s a mess. Will turning it into a game make everything better?

With two small kids and a dog to take care of, I often struggle to look after myself. Self-care apps promise to help – if you can handle the quests, magic potions and rainbow stones. I put four of them to the test

The Guardian - UK

Popular Glasgow restaurant to 'temporarily close' its doors

The National (Scotland)

Apple TV+ hidden Tom Hanks sci-fi gem is like Cast Away meets Fallout – and I love it

Finch flew under the radar at launch

From analysis to the latest developments in health,
read the most diverse news in one place.

How 2023 became the year of the wine bar

A new wave of wine bars is taking the capital’s coolest postcodes by storm and slaking the thirst of younger drinkers. Ben McCormack takes a sip

Evening Standard

Is bottomless prosecco going to be killed off by climate change?

Climate change is threatening prosecco vineyards in Northern Italy. Hannah Twiggs explores what this means for bottomless brunchers, al fresco drinkers and the future of sparkling wines

The Independent UK

5 Boston Fintechs Aiming To Make Your Financial Life Easier

Financial technology, or fintech, is cutting-edge technology used to help improve and automate the delivery of financial services. Fintech companies are not financial institutions, but instead financial applications like Zelle and Venmo that help both businesses and individuals send money faster and easier.

Benzinga

September 2022 appointments and promotions from across the East Midlands

Latest East Midlands appointments include a refugee from war-torn Ukraine

Birmingham Post

Read news from The Economist, FT, and more,
with one subscription

Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26

CNBC The Aviation Sector Is Slammed By Sky-High Rents

Benzinga

U.S. FDA removes Clinical Hold on Finch's investigational new drug (IND) application for CP101

The U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch Therapeutics Group (NASDAQ: FNCH) investigational new drug (IND) application for CP101 in the prevention of recurrent C. difficile infection (CDI).

Benzinga

Finch Therapeutics Cuts 20% Workforce, Realigns Focus On C. Diff, Autism Programs

Finch Therapeutics Group Inc (NASDAQ:FNCH) announced the layoff of 20% of its staff in a regulatory filing. The cuts will impact 37 full-time employees. The FDA in March placed a clinical hold on the Phase 3 trial for CP101, a donor-derived microbiome drug for Clostridioides difficile, as well as a partial hold…

Benzinga

See Why Did Finch Therapeutics Halt Enrolment In Late-Stage C. Difficile Infection Trial

The FDA has issued a clinical hold letter to Finch Therapeutics Group Inc's (NASDAQ:FNCH) PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI). The Company has paused enrollment in the trial as the FDA has asked for additional information about Finch's SARS-CoV-2 donor screening protocols. The FDA placed Finch's investigational new…

Benzinga

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi

Here's a roundup of top developments in the biotech space over the last 24 hours.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.